A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Acronyms NOBILITY
  • Sponsors Roche
  • Most Recent Events

    • 13 Mar 2017 Planned End Date changed from 1 Apr 2020 to 29 Aug 2020.
    • 17 Feb 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
    • 17 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top